GHRS
GH ResearchยทNASDAQ
--
--(--)
--
--(--)
GHRS Profile
Gh Research Plc
A clinical stage biopharmaceutical company that develops novel therpies for the management of mental diseases
Joshua Dawson House, Dawson Street, Dublin 2, D02 RY95, Ireland
--
GH Research PLC was incorporated under the laws of Ireland on 29 March 2021. The company is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of mental and neurological diseases. The company's initial focus was to develop a new patented mebphenolone for the treatment of patients with treatment-resistant depression (TRD). The Company's product portfolio currently includes GH001, the Company's proprietary inhalable 5-MeO-DMT product candidate, delivered via vaporization equipment manufactured by third parties, and GH002, the Company's proprietary injectable 5-MeO-DMT product candidate. The company has completed a Phase 1 healthy volunteer clinical trial in which GH001 administered by inhalation was observed to be well tolerated at the study's single-dose level and individualized dosing regimen, with dose escalation in subjects within one day. GH001 is currently being studied in the Phase 2 portion of a Phase 1/2 clinical trial in patients with TRD.
